{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T23:28:52Z","timestamp":1790724532421,"version":"4.1.0"},"reference-count":53,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T00:00:00Z","timestamp":1763596800000},"content-version":"am","delay-in-days":354,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical and Biophysical Research Communications"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.bbrc.2024.151011","type":"journal-article","created":{"date-parts":[[2024,11,17]],"date-time":"2024-11-17T15:05:31Z","timestamp":1731855931000},"page":"151011","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Synergistic anti-tumor effects of oncolytic virus and anti-programmed cell death protein 1 antibody combination therapy: For suppression of lymph node and distant metastasis in a murine melanoma model"],"prefix":"10.1016","volume":"740","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1953-4366","authenticated-orcid":false,"given":"Yuki","family":"Sasaki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3612-8201","authenticated-orcid":false,"given":"Taku","family":"Maeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Hojo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4180-6556","authenticated-orcid":false,"given":"Takahiro","family":"Miura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6068-7276","authenticated-orcid":false,"given":"Kosuke","family":"Ishikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emi","family":"Funayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazufumi","family":"Okada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhei","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbrc.2024.151011_bib1","doi-asserted-by":"crossref","first-page":"4169","DOI":"10.1245\/s10434-016-5286-0","article-title":"Patterns of clinical response with talimogene laherparepvec (T-VEC) in patients with melanoma treated in the OPTiM phase III clinical trial","volume":"23","author":"Andtbacka","year":"2016","journal-title":"Ann. Surg Oncol."},{"key":"10.1016\/j.bbrc.2024.151011_bib2","article-title":"The dilemma of HSV-1 oncolytic virus delivery: the method choice and hurdles","volume":"24","author":"Tang","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bbrc.2024.151011_bib4","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/j.cell.2017.08.027","article-title":"Oncolytic virotherapy promotes intratumoral T cell infiltration and improves anti-PD-1 immunotherapy","volume":"170","author":"Ribas","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.bbrc.2024.151011_bib5","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1200\/JCO.22.00343","article-title":"Randomized, double-blind, placebo-controlled, global phase III trial of talimogene laherparepvec combined with pembrolizumab for advanced melanoma","volume":"41","author":"Chesney","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bbrc.2024.151011_bib6","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/s12964-022-01012-0","article-title":"Mesenchymal stem cell-released oncolytic virus: an innovative strategy for cancer treatment","volume":"21","author":"Ghasemi Darestani","year":"2023","journal-title":"Cell Commun. Signal."},{"key":"10.1016\/j.bbrc.2024.151011_bib7","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1002\/ijc.34139","article-title":"Distinguishing the pros and cons of metabolic reprogramming in oncolytic virus immunotherapy","volume":"151","author":"Wang","year":"2022","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.bbrc.2024.151011_bib8","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1038\/bjc.2015.481","article-title":"Oncolytic viruses: finally delivering","volume":"114","author":"Seymour","year":"2016","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.bbrc.2024.151011_bib9","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1002\/ijc.33550","article-title":"Oncolytic herpes simplex virus HF10 (canerpaturev) promotes accumulation of CD8+ PD-1- tumor-infiltrating T cells in PD-L1-enriched tumor microenvironment","volume":"149","author":"Eissa","year":"2021","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.bbrc.2024.151011_bib10","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines10010173","article-title":"Systemic injection of oncolytic vaccinia virus suppresses primary tumor growth and lung metastasis in metastatic renal cell carcinoma by remodeling tumor microenvironment","volume":"10","author":"Park","year":"2022","journal-title":"Biomedicines"},{"key":"10.1016\/j.bbrc.2024.151011_bib11","doi-asserted-by":"crossref","DOI":"10.1080\/08916934.2023.2259126","article-title":"Oncolytic virus oHSV2 combined with PD-1\/PD-L1 inhibitors exert antitumor activity by mediating CD4 + T and CD8 + T cell infiltration in the lymphoma tumor microenvironment","volume":"56","author":"Zhang","year":"2023","journal-title":"Autoimmunity"},{"key":"10.1016\/j.bbrc.2024.151011_bib12","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1038\/s41591-021-01510-7","article-title":"Neoadjuvant talimogene laherparepvec plus surgery versus surgery alone for resectable stage IIIB-IVM1a melanoma: a randomized, open-label, phase 2 trial","volume":"27","author":"Dummer","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.bbrc.2024.151011_bib13","first-page":"599","article-title":"Phase I dose-escalation clinical trial of HF10 oncolytic herpes virus in 17 Japanese patients with advanced cancer","volume":"61","author":"Kasuya","year":"2014","journal-title":"Hepato-Gastroenterology"},{"key":"10.1016\/j.bbrc.2024.151011_bib14","doi-asserted-by":"crossref","first-page":"149","DOI":"10.3389\/fonc.2017.00149","article-title":"Genomic signature of the natural oncolytic herpes simplex virus HF10 and its therapeutic role in preclinical and clinical trials","volume":"7","author":"Eissa","year":"2017","journal-title":"Front. Oncol."},{"key":"10.1016\/j.bbrc.2024.151011_bib15","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1093\/annonc\/mdh225","article-title":"Intratumoral injection of herpes simplex virus HF10 in recurrent breast cancer","volume":"15","author":"Nakao","year":"2004","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.bbrc.2024.151011_bib16","doi-asserted-by":"crossref","first-page":"9543","DOI":"10.1200\/JCO.2016.34.15_suppl.9543","article-title":"Preliminary results from phase II study of combination treatment with HF10, a replication-competent HSV-1 oncolytic virus, and ipilimumab in patients with stage IIIb, IIIc, or IV unresectable or metastatic melanoma","volume":"34","author":"Andtbacka","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bbrc.2024.151011_bib17","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1080\/00016480600702100","article-title":"Intratumoral injection of herpes simplex virus HF10 in recurrent head and neck squamous cell carcinoma","volume":"126","author":"Fujimoto","year":"2006","journal-title":"Acta Otolaryngol."},{"key":"10.1016\/j.bbrc.2024.151011_bib18","doi-asserted-by":"crossref","first-page":"6082","DOI":"10.1200\/jco.2014.32.15_suppl.6082","article-title":"Phase I trial of intratumoral therapy using HF10, an oncolytic HSV-1, demonstrates safety in HSV+\/HSV- patients with refractory and superficial cancers","volume":"32","author":"Ferris","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bbrc.2024.151011_bib19","first-page":"683","article-title":"S-1 facilitates canerpaturev (C-REV)-induced antitumor efficacy in a triple-negative breast cancer model","volume":"83","author":"Miyajima","year":"2021","journal-title":"Nagoya J. Med. Sci."},{"key":"10.1016\/j.bbrc.2024.151011_bib20","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-022-25065-w","article-title":"Metformin enhances the antitumor activity of oncolytic herpes simplex virus HF10 (canerpaturev) in a pancreatic cell cancer subcutaneous model","volume":"12","author":"Abdelmoneim","year":"2022","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bbrc.2024.151011_bib21","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1038\/jid.2012.274","article-title":"Pathophysiological characteristics of melanoma in-transit metastasis in a lymphedema mouse model","volume":"133","author":"Oashi","year":"2013","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.bbrc.2024.151011_bib22","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1002\/ijc.31414","article-title":"Immune-mediated antitumor effect of a transplanted lymph node","volume":"143","author":"Maeda","year":"2018","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.bbrc.2024.151011_bib23","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1089\/lrb.2016.0070","article-title":"Lymphatic reconnection and restoration of lymphatic flow by nonvascularized lymph node transplantation: real-time fluorescence imaging using indocyanine green and fluorescein isothiocyanate-dextran","volume":"16","author":"Maeda","year":"2018","journal-title":"Lymphatic Res. Biol."},{"key":"10.1016\/j.bbrc.2024.151011_bib24","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1038\/bjc.2013.115","article-title":"Tyrosinase-related protein 1 mRNA expression in lymph node metastases predicts overall survival in high-risk melanoma patients","volume":"108","author":"El Hajj","year":"2013","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.bbrc.2024.151011_bib25","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1038\/nri.2016.55","article-title":"C-type lectin receptors in the control of T helper cell differentiation","volume":"16","author":"Geijtenbeek","year":"2016","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.bbrc.2024.151011_bib26","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.immuni.2009.05.001","article-title":"Plasticity of CD4+ T cell lineage differentiation","volume":"30","author":"Zhou","year":"2009","journal-title":"Immunity"},{"key":"10.1016\/j.bbrc.2024.151011_bib27","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1002\/1096-9896(2000)9999:9999<::AID-PATH729>3.0.CO;2-D","article-title":"Expression of gp100, MART-1, tyrosinase, and S100 in paraffin-embedded primary melanomas and locoregional, lymph node, and visceral metastases: implications for diagnosis and immunotherapy. A study conducted by the EORTC Melanoma Cooperative Group","volume":"193","author":"de Vries","year":"2001","journal-title":"J. Pathol."},{"key":"10.1016\/j.bbrc.2024.151011_bib28","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s11864-019-0607-8","article-title":"Targeted therapy and immunotherapy for melanoma in Japan","volume":"20","author":"Namikawa","year":"2019","journal-title":"Curr. Treat. Options Oncol."},{"key":"10.1016\/j.bbrc.2024.151011_bib29","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1016\/S0140-6736(22)00562-1","article-title":"Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial","volume":"399","author":"Luke","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.bbrc.2024.151011_bib30","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/S0140-6736(17)31601-X","article-title":"Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006)","volume":"390","author":"Schachter","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.bbrc.2024.151011_bib31","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1056\/NEJMoa1709684","article-title":"Overall survival with combined nivolumab and ipilimumab in advanced melanoma","volume":"377","author":"Wolchok","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbrc.2024.151011_bib32","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1016\/S1470-2045(16)30126-7","article-title":"Sequential administration of nivolumab and ipilimumab with a planned switch in patients with advanced melanoma (CheckMate 064): an open-label, randomised, phase 2 trial","volume":"17","author":"Weber","year":"2016","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.bbrc.2024.151011_bib33","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1111\/1346-8138.16669","article-title":"Updated analysis of nivolumab and ipilimumab combination therapy in Japanese patients with advanced melanoma","volume":"50","author":"Takahashi","year":"2023","journal-title":"J. Dermatol."},{"key":"10.1016\/j.bbrc.2024.151011_bib34","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1056\/NEJMoa2109970","article-title":"Relatlimab and nivolumab versus nivolumab in untreated advanced melanoma","volume":"386","author":"Tawbi","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbrc.2024.151011_bib35","doi-asserted-by":"crossref","first-page":"2724","DOI":"10.1200\/JCO.22.02072","article-title":"Nivolumab and relatlimab in patients with advanced melanoma that had progressed on anti-programmed death-1\/programmed death ligand 1 therapy: results from the phase I\/IIa RELATIVITY-020 trial","volume":"41","author":"Ascierto","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bbrc.2024.151011_bib36","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1016\/S1470-2045(18)30700-9","article-title":"Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial","volume":"19","author":"Hodi","year":"2018","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.bbrc.2024.151011_bib37","doi-asserted-by":"crossref","first-page":"11","DOI":"10.2147\/OV.S100072","article-title":"Oncolytic virotherapy including Rigvir and standard therapies in malignant melanoma","volume":"6","author":"Babiker","year":"2017","journal-title":"Oncolytic Virotherapy"},{"key":"10.1016\/j.bbrc.2024.151011_bib38","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.canlet.2021.06.005","article-title":"Enhanced anti-tumor response elicited by a novel oncolytic HSV-1 engineered with an anti-PD-1 antibody","volume":"518","author":"Tian","year":"2021","journal-title":"Cancer Lett."},{"key":"10.1016\/j.bbrc.2024.151011_bib39","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.omto.2022.01.003","article-title":"Immune priming using DC- and T cell-targeting gene therapy sensitizes both treated and distant B16 tumors to checkpoint inhibition","volume":"24","author":"Wenthe","year":"2022","journal-title":"Mol Ther Oncolytics"},{"key":"10.1016\/j.bbrc.2024.151011_bib40","doi-asserted-by":"crossref","first-page":"6190","DOI":"10.1158\/1078-0432.CCR-17-0681","article-title":"Local delivery of OncoVEX(mGM-CSF) generates systemic antitumor immune responses enhanced by cytotoxic T-lymphocyte-associated protein blockade","volume":"23","author":"Moesta","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bbrc.2024.151011_bib41","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/S1470-2045(06)70975-5","article-title":"Immunobiology of the sentinel lymph node and its potential role for antitumour immunity","volume":"7","author":"Kim","year":"2006","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.bbrc.2024.151011_bib42","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1146\/annurev.immunol.19.1.47","article-title":"Cross-presentation, dendritic cells, tolerance and immunity","volume":"19","author":"Heath","year":"2001","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.bbrc.2024.151011_bib43","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1038\/ni957","article-title":"Antigen presentation to naive CD4 T cells in the lymph node","volume":"4","author":"Itano","year":"2003","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.bbrc.2024.151011_bib44","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1002\/ijc.34059","article-title":"CD8 agonism functionally activates memory T cells and enhances antitumor immunity","volume":"151","author":"Madi","year":"2022","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.bbrc.2024.151011_bib45","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.cytogfr.2010.02.014","article-title":"Impact of tumor microenvironment on oncolytic viral therapy","volume":"21","author":"Wojton","year":"2010","journal-title":"Cytokine Growth Factor Rev."},{"key":"10.1016\/j.bbrc.2024.151011_bib46","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1006\/mthe.2000.0240","article-title":"Development of a syngenic murine B16 cell line-derived melanoma susceptible to destruction by neuroattenuated HSV-1","volume":"3","author":"Miller","year":"2001","journal-title":"Mol. Ther."},{"key":"10.1016\/j.bbrc.2024.151011_bib47","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1038\/nri.2017.146","article-title":"Epigenetic control of CD8+ T cell differentiation","volume":"18","author":"Henning","year":"2018","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.bbrc.2024.151011_bib48","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1080\/08820139.2020.1765795","article-title":"Microspheres encapsulating immunotherapy agents target the tumor-draining lymph node in pancreatic ductal adenocarcinoma","volume":"49","author":"Han","year":"2020","journal-title":"Immunol. Invest."},{"key":"10.1016\/j.bbrc.2024.151011_bib49","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/j.immuni.2024.02.007","article-title":"CD4(+) T cell activation distinguishes response to anti-PD-L1+anti-CTLA4 therapy from anti-PD-L1 monotherapy","volume":"57","author":"Franken","year":"2024","journal-title":"Immunity"},{"key":"10.1016\/j.bbrc.2024.151011_bib50","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1038\/nri3831","article-title":"Type 2 cytokines: mechanisms and therapeutic strategies","volume":"15","author":"Wynn","year":"2015","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.bbrc.2024.151011_bib51","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1016\/j.immuni.2013.10.010","article-title":"The spleen in local and systemic regulation of immunity","volume":"39","author":"Bronte","year":"2013","journal-title":"Immunity"},{"key":"10.1016\/j.bbrc.2024.151011_bib52","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1001\/jamaoncol.2015.1184","article-title":"Efficacy and safety of nivolumab in patients with BRAF V600 mutant and BRAF Wild-type advanced melanoma: a pooled analysis of 4 clinical trials","volume":"1","author":"Larkin","year":"2015","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.bbrc.2024.151011_bib53","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-006270","article-title":"Talimogene laherparepvec in combination with ipilimumab versus ipilimumab alone for advanced melanoma: 5-year final analysis of a multicenter, randomized, open-label, phase II trial","volume":"11","author":"Chesney","year":"2023","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.bbrc.2024.151011_bib54","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.1038\/s41591-023-02498-y","article-title":"Ipilimumab with or without nivolumab in PD-1 or PD-L1 blockade refractory metastatic melanoma: a randomized phase 2 trial","volume":"29","author":"VanderWalde","year":"2023","journal-title":"Nat. Med."}],"container-title":["Biochemical and Biophysical Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X2401547X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X2401547X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,12]],"date-time":"2025-02-12T07:04:20Z","timestamp":1739343860000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006291X2401547X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":53,"alternative-id":["S0006291X2401547X"],"URL":"https:\/\/doi.org\/10.1016\/j.bbrc.2024.151011","relation":{},"ISSN":["0006-291X"],"issn-type":[{"value":"0006-291X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Synergistic anti-tumor effects of oncolytic virus and anti-programmed cell death protein 1 antibody combination therapy: For suppression of lymph node and distant metastasis in a murine melanoma model","name":"articletitle","label":"Article Title"},{"value":"Biochemical and Biophysical Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbrc.2024.151011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"151011"}}